Clinical Trial: KRAS G12D-specific Immune Effector Cells Targeting KRAS G12D-positive Solid Tumors

U.S., Nov. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07924449) titled 'KRAS G12D-specific Immune Effector Cells Targeting KRAS G12D-positive Solid Tumors' on Nov. 03.

Brief Summary: The purpose of this study is to assess the feasibility, safety and efficacy of KRAS G12D-specific engineered immune effector (EIE) therapy in patients with advanced, KRAS G12D-positive malignancies. Another goal of the study is to characterize the function, expansion and persistence of KRAS G12D-specific effector cells in treated patients.

Study Start Date: Nov. 03

Study Type: INTERVENTIONAL

Condition: Advanced Malignant Tumors With KRAS G12D Mutation

Intervention: BIOLOGICAL: KRAS G12D-EIEs

1 to 2 infusions, once a ...